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Introduction
A recent report in the New England Journal of Medi-
cine chronicled an outbreak of hypoglycaemia in
patients using counterfeit sexual enhancement drugs
(1). Glyburide, a powerful drug used for the treat-
ment of diabetes, was found to be a contaminant in
counterfeit tadalaﬁl and herbal preparations for the
treatment of erectile dysfunction (ED) (1). Of the
150 non-diabetic patients admitted to hospitals in
Singapore, seven patients were comatose as a result
of severe neuroglycopenia; four patients subsequently
died (1).
This case is just one of many that report the dan-
gers inherent in counterfeit drugs. Other examples
include two women in Argentina who died after
being given injections of a counterfeit iron prepara-
tion to treat anaemia; another woman survived but
had a 26-week premature baby (2). The prevalence
of counterfeit artesunate, an antimalarial drug, has
been increasing in Southeast Asia. Without the
required active ingredients, patients have died, and
the cause of death was often mistakenly attributed to
drug resistance (3). In Bangladesh, at least 51
children died in an outbreak of diethylene glycol
poisoning of paracetamol syrup, with many more
victims suspected (4). Diethylene glycol contami-
nation of paracetamol syrup was responsible for an
estimated 192,000 deaths in 2002 (5).
Although death is the most extreme consequence
of counterfeit medication, other dangers of counter-
feits are more widespread. Counterfeit drugs may
contain excessive or ineffective levels of active ingre-
dients, contaminants, or inactive or dangerous ingre-
dients. For example, tap water has been found as the
only ingredient in counterfeit neomycin eye drops
and meningococcal vaccine, counterfeit ampicillin
consisting of turmeric and counterfeit contraceptive
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feit antibiotics and snake antivenom (in addition to
antimalarials) have been found to lack active ingredi-
ents (6).
What is a counterfeit drug and how big is the
problem?
The deﬁnition of counterfeit drugs varies between
countries, but the World Health Organization
(WHO) deﬁnes counterfeit medicines as those that
‘are deliberately and fraudulently mislabelled with
respect to identity or source: their quality is unpre-
dictable as they may contain the wrong amount of
active ingredients, wrong ingredients or no active
ingredients…[they are] manufactured in clandestine
laboratories with no possibility of control (2).’
The prevalence of counterfeit drugs appears to be
increasing; however, the scale of an illicit industry is
difﬁcult to determine. Counterfeit seizures in the
European Union increased 384% between 2005 and
2006 (7), with a further 51% increase in 2007 (8).
Customs ofﬁcials noted that counterfeits were
becoming more difﬁcult to distinguish from their
genuine counterparts (9).
In the United States, the number of investigations
by the Food and Drug Administration (FDA) into
drug fraud in 2003 was almost four times that in
2000 (10). Additionally, the FDA also noted
increased complexity and organisation of the coun-
terfeit medication industry (10). The FDA has seen
an 800% increase in the number of new counterfeit
cases between 2000 and 2006 (11). The Center for
Medicine in the Public Interest estimates that the
global sales of counterfeit drugs will reach $75 billion
in 2010, a 92% increase from 2005 (11,12).
In most developed countries with effective regu-
latory systems and market control, it is estimated that
< 1% of sales are counterfeit, although many indica-
tions point to an increasing prevalence of counterfeits
(13). Overall, approximately 10–30% of medications
in developing markets may be counterfeit (13). Some
countries of Africa, parts of Asia and parts of Latin
America have areas where more than 30% of the
medicines on sale can be counterfeit; many former
Soviet republics have a proportion close to 20% (13).
Given the scope of the problem, the number of people
who may be exposed to adverse events with counter-
feit drug use is substantial.
How are phosphodiesterase type 5 inhibitors
related to counterfeit drugs?
The growth in counterfeit medications is partly
because of the advent of effective oral medications
for ED (14); sildenaﬁl (Viagra
 ; Pﬁzer Inc, New
York, NY, USA) and other phosphodiesterase type 5
inhibitors [PDE5is, including tadalaﬁl (Cialis
 ; Eli
Lilly and Company, Indianapolis, IN, USA) and var-
denaﬁl (Levitra
 ; Bayer HealthCare, Wayne, NJ,
USA)] are the drugs most likely to be counterfeited.
According to EU counterfeit seizures, PDE5is were
the most commonly counterfeited class of product in
Europe (15); they are a prime target for counterfeit-
ing because of their high cost and the embarrassment
associated with the underlying condition (14).
During the 5 years spanning from 2004 to 2008,
35.8 million counterfeit sildenaﬁl tablets were seized
in Europe. In 2004, law ofﬁcers seized 10.6 million
counterfeit sildenaﬁl tablets, which was seven times
the number of all other counterfeited Pﬁzer products
combined (16). In 2006, 2.5 million counterfeit silde-
naﬁl tablets were seized in the European Union and
accounted for 96% of the counterfeit Pﬁzer products
seized (16). In 2007, 3.4 million counterfeit sildenaﬁl
tablets were seized (16).
Two different analyses estimated the market size
for illicit sildenaﬁl (16). From these analyses, it was
estimated that 0.6–2.5 million men in Europe could
be exposed to illicit sildenaﬁl. For comparison, IMS
Health (Norwalk, CT) estimates the number of users
of legal sildenaﬁl in the European Union to be
2.5 million in 2006.
What is in counterfeit phosphodiesterase type
5 inhibitors?
At least some active ingredient was present in the
counterfeit Viagra that was seized by the Medical
Control Agency of the United Kingdom (40–100% of
the labelled dosage) (17). A portion (n = 2383) of the
pharmaceutical agents seized by authorities (including
customs, law enforcement and health agencies) for
suspicion of being counterfeit Viagra were forwarded
to Pﬁzer for analysis between 2005 and 2009 (18).
Spectral analysis determined authenticity of samples
and high-performance liquid chromatography deter-
mined purity and active pharmaceutical ingredient
(API) concentration in a subset of samples. Inconsis-
tent dosage of API (0% to > 200% of the indicated
strength of sildenaﬁl, Figure 1), as well as impurities
or alternative ingredients with potentially hazardous
substances were found.
Only 10.1% of samples labelled ‘Viagra 100 mg’
were within 10% of the advertised tablet strength
(Figure 1). A sample of counterfeit Viagra from
Hungary was found to contain only amphetamine, a
stimulant with potent adverse effects. Counterfeit
Viagra seized in the United Kingdom contained caf-
feine and bulk lactose, with only 30 mg of the adver-
tised 100 mg of sildenaﬁl citrate. Talcum powder,
commercial-grade paints, and active ingredients for
completely different pharmaceuticals have been
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Paracetamol and metronidazole, an antiproto-
zoal⁄anti-infective, have been found in counterfeit
Viagra. Metronidazole has signiﬁcant adverse effects
when combined with alcohol; overdose of paraceta-
mol can cause potentially fatal liver damage, with
alcohol intake and alcoholism signiﬁcantly increasing
this risk (19,20). Printer ink has been used to colour
tablets blue. Additionally, large quantities of uniden-
tiﬁed impurities have been found in counterfeit
tablets.
The Dutch National Institute for Public Health
and Environment (RIVM) analysed 370 samples of
illegally sold Viagra collected from 2000 to 2004 and
found that only 10 were genuine (21). Often, sildena-
ﬁl was present, but in lower amounts than declared.
In addition, other pharmaceuticals, such as amphet-
amine, clomiphene, chloramphenicol, dipyrone,
ﬂuoxetine, tadalaﬁl, yohimbine, gamma-amino buty-
ric acid, caffeine, l-arginine, indigotin and quinine
were found in seized samples (21).
In a follow-up survey by three governmental labo-
ratories in the Netherlands (RIVM, the Nederlands
Forensisch Instituut, and the Douane Laboratorium),
an increased number of imitation erectogenic prod-
ucts (deﬁned as illegal drug products that do not
look like the genuine medicine, but by their name or
claim strongly suggest an erectogenic effect) was
found, from 50% in 2000 to 2004 to 65% in 2005 to
2006 (22). The most commonly found imitation was
Kamagra, a sildenaﬁl-containing medication that is
manufactured by a legitimate Indian pharmaceutical
company; however, this compound is not licensed in
the European Union or the United States. Sildenaﬁl
was found in 69% of the 95 uncontrolled (i.e. coun-
terfeit and imitation) erectogenic products, including
Kamagra. Tadalaﬁl, which had represented only 2%
of samples in the previous analysis, accounted for
25% of samples and vardenaﬁl accounted for 6%
(22).
The US National Association of State Boards of
Pharmacy (NABP) ordered several different medica-
tions, including Cialis from 13 suspicious websites
selling prescription-only medication without a pre-
scription (23). The FDA analysed the active ingredi-
ents and found wide variation in the amount
present, ranging from none to far exceeding the
level allowed in US medications (23). Lilly, the drug
manufacturer, performed a regulatory analysis on
the products obtained by NABP and found that
they did not meet the company’s US standards
(23).
‘Herbal’ or ‘dietary’ supplements are also marketed
for sexual dysfunction, and consumers may believe
these products to be harmless (24). When 17 com-
mercial formulations were analysed, eight contained
approved PDE5is or related compounds, including
sildenaﬁl, tadalaﬁl, vardenaﬁl, hydroxyhomosildenaﬁl,
thiosildenaﬁl and thiomethisosildenaﬁl (25). An anal-
ysis of a ‘100% natural product’ for ED that was
purchased over the counter and directly from the
manufacturer using the Internet revealed that the
three samples analysed contained an average of
55 mg of sildenaﬁl per capsule (26).
What are the dangers of counterfeit
phosphodiesterase type 5 inhibitors?
Direct risks
The presence of unknown pharmaceutically active
ingredients and⁄or impurities may lead to undesir-
able and serious adverse events or even death. Dos-
age variability and dosage mislabelling may lead to
accidental overdose. Additionally, incorrect or
incomplete descriptions of product composition cre-
ate a substantial risk for drug–drug interactions.
Minimal or incorrect guidance about contraindica-
tions may lead to serious adverse events. Because
inert ingredients provide no treatment beneﬁt,
patients remain untreated and may be discouraged
from seeking additional help because they believe
that medication does not work for them.
Indirect risks
Unsupervised use of PDE5is, particularly by men
with ED and common comorbid conditions (e.g.
hypertension, dyslipidaemia and diabetes) may occur.
Because these diseases carry a signiﬁcant risk of mor-
bidity or mortality, men who omit a physician visit
to discuss their ED also lose an opportunity to
address potential underlying conditions. This is a
concern because men with health problems have
Figure 1 Sildenaﬁl dosage of counterfeit products
(n = 316) analysed by Pﬁzer Samples were labelled as
‘Viagra 100 mg’
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a physician (27).
Using drugs that are not what they are supposed
to be provides no basis for determining drug efﬁcacy
or providing guidance for future use. Importantly,
addressing adverse events of an unknown product is
difﬁcult and perhaps dangerous, as illustrated by the
glyburide contamination incident described earlier.
Statistics for adverse events and fatalities resulting
from counterfeit products appear low relative to the
amount of illicit PDE5is available. However, suppli-
ers work outside any regulatory authority, which
makes defects and adverse drug reactions difﬁcult to
recognise, monitor or recall (28).
The role of the Internet
Counterfeit PDE5is are closely associated with the
Internet. The majority of counterfeit PDE5is in the
United States are thought to enter the market via
fraudulent websites (29). In Europe, the Experts on
the Operation of European Conventions in the Penal
Field estimate that 44% of sildenaﬁl sold over the
Internet is counterfeit (30). Between 4500 and 15,000
websites sell PDE5is and other substances used to
treat ED (29), although other estimates place this
number at 500,000 (31). Sites receive 12.9 million
visitors per month and sell approximately 2.3 million
tablets per month, most without a prescription (29).
Evidence indicates that the Internet is generally
unsafe for the purchase of medications. The Euro-
pean Alliance for Access to Safe Medicines (EAASM),
a pan-European patient safety initiative committed
to promoting the exclusion of counterfeit and sub-
standard medicines from the supply chain, examined
the general safety of online pharmacies (32). Of more
than 100 online pharmacies identiﬁed and assessed,
93.8% had no named, veriﬁable pharmacist; 90.3%
did not require a prescription for prescription-only
medications; 84.5% did not have a physical location;
and 78.8% had a website that violated intellectual
property (32). When two orders of 18 different pre-
scription-only medications (including PDE5is) were
placed online without a prescription, 38% were gen-
uine branded medicine (although 16% of these were
illegal non-EU imports and 33% had no patient
information leaﬂet). The remaining 62% were sub-
standard or counterfeit medicine; 68% of these were
‘generic’ imitations and 32% were branded (32).
Similar ﬁndings by other groups echo these star-
tling statistics. WHO has suggested that medicines
purchased over the Internet from sites that conceal
their physical address are counterfeit ‡ 50% of the
time (2). The president of America’s Watchdog, a
consumer advocacy group, has stated that 90% of all
medicines sold over the Internet are fake (33).
Despite these risks, many persons are using the
Internet to buy medication. According to a study of
935 men aged ‡ 35 years in major UK cities, 1 in 10
men has purchased a prescription-only medication
without a prescription, and 50% of those men do so
via the Internet (14,34). The percentage of men pur-
chasing prescription-only medications without a pre-
scription via the Internet increases to 67% when
considering ED medications speciﬁcally (14).
Additionally, a survey of French men (n = 301)
found that even among men with valid prescriptions
for a PDE5i, 12% obtained their ED treatment via
the Internet (16). In another study conducted in
March 2007 in several European countries, six of 51
men in Spain and the United Kingdom reported
using a non-registered and uncontrolled ‘generic’
version of sildenaﬁl, called Kamagra, which is usually
sold over the Internet (16).
Phosphodiesterase type 5 inhibitors ordered
via the Internet are associated with risky
behaviour
Circumvention of primary care is the very ﬁrst risk
associated with Internet-ordered medication. An
Internet-based observational analysis of the sources
used by men in the United Kingdom, Germany and
France who obtained PDE5is within the last
12 months (n = 373) was conducted (35). The
sources of purchase were either within the healthcare
system (HCS), deﬁned as any supply through retail
pharmacy, prescription or a free sample from a phy-
sician; or outside the HCS, deﬁned as Internet or
mail-order pharmacy without a prescription or
uncontrolled sources such as non-pharmacy Internet
sources or from a friend or partner.
Overall, 30.6% of participating men had no inter-
action with the HCS. Signiﬁcant discrepancies were
evident between countries: in the United Kingdom,
48.4% of men used sources outside the HCS,
whereas 27.6% of German men and 15.3% of French
men used sources outside the HCS (Figure 2). Age
discrepancies also were evident: 40.7% of men
18–40 years of age used sources outside the HCS,
whereas 29.0% of those 41–60 years and 14.6% of
those ‡ 61 years did so.
Of men who reported using sources outside the
HCS, 72% reported having ED (43% mild, 25%
moderate, 4% severe), which, as discussed above,
may be associated with common cardiovascular risk
factors (36). Additionally, the probability of hearing
about known contraindications of ED treatments was
likely reduced. Furthermore, men who reported
using sources outside the HCS were more likely to
purchase a ‘generic’ imitation PDE5i than those who
used sources within the HCS (35).
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10.5% of almost 12,000 men in an Internet-based
observational study conducted in the United King-
dom, Germany and Italy reported PDE5i use in the
previous 6 months (37). Almost one-third (32.3%)
of men obtained their PDE5i without healthcare pro-
fessional (HCP) interaction. HCP interaction was
deﬁned as having a prescription for a PDE5i, having
a sample of PDE5i from a physician, or buying the
PDE5i in a retail pharmacy; non-HCP sources
included friends, the Internet and partners or other
acquaintances. More men without HCP interaction
than with HCP interaction used the Internet to pur-
chase their medication (51.6% vs. 27.6%). More than
60% of men who bypassed HCP interaction to
obtain their PDE5i believed they would get the same
prescription-only medication via the Internet
(Figure 3). The majority of men were not concerned
about the efﬁcacy of medicines ordered via the Inter-
net, although most generally felt that medicines sold
via the Internet were less safe than those prescribed
by a physician (Figure 3). Of men bypassing HCP
interaction, 65.5% genuinely had ED. Thus, a signiﬁ-
cant number of men missed the opportunity for
evaluation of possible morbidities that coexist with
ED.
Substantive evaluations are not offered by the
‘cyberdoctors’ used by many Internet sites to create
prescriptions (38). It is unclear whether these cyber-
doctors are real people or merely computer pro-
grams; their credentials may not exist (39). Some
sites have disclaimers stating that physicians may not
reside in the same country as the patient or the
pharmacy. Alarmingly, patients with obvious contra-
indications to sildenaﬁl use have been prescribed the
drug (40).
The circumvention of the HCS is not the only risk
associated with Internet purchase of PDE5is. Men
who buy PDE5is via the Internet appear to use more
pills than those who do not. A survey of purchasing
channels for men in the United Kingdom, France
and Germany revealed that men who obtained silde-
naﬁl from a pharmacy or directly from a physician
consumed an average of 13 pills within the last
(a)
(b)
Figure 2 Distribution of men who interacted within or
outside the healthcare system (HCS) to obtain
phosphodiesterase type 5 inhibitors by (a) country and (b)
age. A chi-square test was used to test associations,
statistical tests were two-tailed, and the Bonferroni-Holm
sequential step-down method was applied to control the
overall alpha level, set at 0.05
100 20 0
Percentage of subjects agreeing
40 60 80
With HCP, with ED (n = 201)
With HCP, without ED (n = 148)
Without HCP, with ED (n = 161)
Without HCP, without ED (n = 128)
Nonuser, with ED (n = 191)
Nonuser, without ED (n = 212)
The same medication for ED that
physicians prescribe is available
through internet sources.
I am concerned about the privacy
of my personal information when
purchasing medication from
internet sites.
I am concerned that the efficacy of the
medication purchased from internet
sites may not be the same as
medications prescribed by physicians.
Medications purchased from the
internet are as safe as medications
prescribed by physicians.
Figure 3 Attitudes towards phosphodiesterase type 5 inhibitors obtained via the Internet. ED, erectile dysfunction; HCP,
healthcare professional. Reproduced from Schnetzler et al. (37) with permission from Blackwell Publishing Ltd.
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Internet consumed 20 pills and those taking unau-
thorised generics consumed 29 pills in the same time
period (16). Thus, patients purchasing through the
Internet have increased risk of exposure to counter-
feit PDE5is. Phosphodiesterase type 5 inhibitors are
associated with intentional abuse or recreational use
in certain subpopulations, and surveys indicate that
the Internet is a source for recreational PDE5is (41).
Further, sources of information about abusing
PDE5is, such as methods to enhance or exaggerate
expected effects, are readily found on the Internet
(41).
What can be done to combat counterfeit
phosphodiesterase type 5 inhibitors and other
drugs?
The WHO has stated, ‘Counterfeit medicines are a
threat to our communities and must be stopped.
This problem is not isolated to a handful of coun-
tries; it is present everywhere and it is gaining
momentum. It is not a problem of one person, it is
a problem of all people. It is not a problem of one
country, it is a problem of all nations (42).’
To combat the problem, there is a general consen-
sus that increased obstacles for counterfeiters are
necessary to reduce risks associated with counterfeit
drugs as well as their sale via the Internet
(2,6,11,15,43–47). However, a clear worldwide con-
sensus on what constitutes a counterfeit drug is lack-
ing. Activities associated with counterfeit drug
manufacturing and distribution may be illegal in
some countries but not in others. For example, India
and China do not recognise European patent author-
ity and can legally manufacture generic drugs that
would be illegal to produce in the United Kingdom
(48). However, the United Kingdom legally permits
importation of products for personal use that are
licensed in the country of origin, including those
ordered via the Internet (5,48). From January to July
of 2005, > 250 kg of sildenaﬁl citrate was exported
from India to European destinations; 1 kg can pro-
duce approximately 14,000 counterfeit Viagra tablets
(49). When sold at market price, 2000% proﬁts can
be realised, which is approximately 10 times the
proﬁtability of heroin (49). This type of proﬁt comes
with comparatively little risk: in the United King-
dom, it has been reported that the prison sentence
and ﬁne for counterfeiting a T-shirt with a trade-
marked logo can be greater than for counterfeiting a
medicine (11).
Because of the worldwide nature of the counter-
feiting problem, proper coordination between coun-
tries is absolutely essential (17). However, many
countries lack the resources and⁄or political will-
power to prioritise an anticounterfeiting agenda.
Countries interested in prosecuting counterfeiters
are hindered by a lack of international cooperation.
For example, in the United States, only counterfeit-
ing operations that take place on US soil or involve
directly misleading regulatory authorities are prose-
cuted; diplomatic obstacles and varying laws
between countries are some of the many hindrances
to action (28). Jurisdiction within the United States
has been described as confusing and overlapping
(50). The UK’s Medicines and Healthcare Products
Regulatory Agency continually monitors Internet
sites that sell prescription-only medications, but is
only able to take action against sites based in the
United Kingdom (51). Overseas sites are referred to
the regulatory body of their country of operation
(51).
Implementation of ﬁnes and penalties is often pro-
posed as a solution, but in practice, collection is far
from simple (52). Resources and dedication to
enforcement of tough penalties are needed to deter
the dangerous practice of counterfeiting medications.
Unfortunately, it will be difﬁcult to deﬁne success
because the extent of the current level of risk is
unknown (53).
For ED speciﬁcally, the threat of Internet-associ-
ated purchase of PDE5is is not fully recognised. Lack
of awareness by HCPs and consumers has been cited
by the WHO’s International Medical Products Anti-
Counterfeiting Taskforce as a key factor that makes
counterfeiting possible (2), a sentiment echoed by
others involved in investigating counterfeit medica-
tions (47). In the study of 935 UK men described
earlier, 32% regarded taking prescription-only medi-
cation without a prescription as a low or neutral risk.
However, 60% admitted that knowing that their
medication was counterfeit would affect the likeli-
hood of purchase, even though most were unsure of
the speciﬁc adverse effects such a purchase may pose
(14,34).
The EAASM believes that informing patients of
possible risks associated with Internet purchasing
of medications will increase awareness (32). Cam-
paigns organised by governments and industry and
directed at consumers have been launched. Physi-
cians who treat ED should inform patients of the
dangers of ordering PDE5is via the Internet as part
of a multipronged strategy to combat counterfeit-
ing.
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